Abstract-After a plutonium-contaminated wound, the role of an internal dosimetrist is to inform the patient and the physician of the dosimetric considerations. The doses averted due to medical treatments (excision or chelation) are higher if the treatments are administered early; therefore, the internal dosimetrist needs to rely on limited information on wound counts and process knowledge for advising the physician. Several wound cases in the literature were reviewed to obtain estimates of the efficacies of surgical excision and chelation treatment after plutonium-contaminated wounds. The dose coefficients calculated by coupling the NCRP 156 wound model with the systemic model were used to derive the decision guidelines that may indicate medical treatment based on 1) the concept of saved doses proposed by the NCRP 156 wound model, 2) the limits recommended by the CEC/DOE guidebook, and 3) the Clinical Decision Guidelines proposed in NCRP Report No. 161. These guidelines by themselves, however, are of limited use for several reasons, including 1) large uncertainties associated with wound measurements, 2) exposure to forms of radionuclides that cannot be assigned to a single category in the NCRP 156 framework, 3) inability of the NCRP 156 model to explain some of the wound cases in the literature, 4) neglect of the local doses to the wound site and the pathophysiological response of the tissue, 5) poorly understood relationship between effective doses and risks of late health effects, and 6) disregard of the psychological aspects of radionuclide intake. Health Phys. 114(3): 307-318; 2018 
INTRODUCTION
INHALATION AND ingestion pathways are considered to be the dominant pathways of intake of radioactive materials into the human body-the former being important for occupational exposures and the latter for public exposures. In addition to these pathways, radioactive material may also enter the body via the wound pathway; i.e., by penetrating wounds produced by contaminated sharp objects or by surface contamination of an open wound. The wound pathway has been and will continue to be a significant contributor of internal dose particularly for workers in the nuclear industry (Hammond and Putzier 1964; Guilmette 2002; Schadilov et al. 2010 ). As such, guidelines on medical management of actinide-contaminated wounds is of great interest to the health physics community.
Contaminated wounds present potential harmful effects to the wound site from local irradiation and serve as a continuous input of radioactive materials into the systemic circulation. These hazards remain until the contaminant itself or the contaminated tissues are removed by decontamination, surgical excision, or radioactive decay. The latter is impractical for radionuclides such as actinides that have long half-lives. Cleansing and copiously irrigating the wound with saline solution or other commercially available cleansers may prevent rapid incorporation of radionuclides into the body to a certain extent (NCRP 2006; Mannis and Brandl 2015) . Depending on the physico-chemistry of the contaminant, as well as the depth, extent, and the location of the wound, some fraction of the activity deposited in the wound may be removed by surgical excision. In fact, a review of records and literature show that excisions are frequent following a wound incident at several plutonium production and weapon development complexes (Johnson and Lawrence 1974; Sudman 1992; NCRP 2006) . Such surgery may either involve removal of the contaminant itself or of the contaminated tissues.
The descriptions as well as management of contaminated wound cases are abundant in the scientific literature. A review by Ilyin (2001) reported the presence of more than 2,100 radionuclide-contaminated wounds, a majority of which involved transuranic radionuclides. Because some of the largest internal doses in history have been due to wounds contaminated with plutonium, this paper focuses on plutonium-contaminated wounds. When the wound involves plutonium, wound excisions are typically accompanied by chelation treatment, which helps to decrease the committed dose by increasing excretion of the radionuclide in excreta, primarily urine.
The benefits of diethylenetriamine pentacetic acid (DTPA) administration after an intake of plutonium or americium have been well documented in the health physics literature. DTPA has been used to treat actinide intakes in the United States since the 1960s and is approved by the U.S. Food and Drug Administration (FDA) for treatment of individuals with internal depositions of plutonium, americium, or curium (USFDA 2004) . Significant reduction in body burdens (and hence reduction in the dose received) have been achieved due to multiple chelation treatments after a wound intake (Jech et al. 1972; Schofield and Lynn 1973; Schofield et al. 1974; IAEA 1978; Poudel et al. 2017a; Avtandilashvili et al. 2017) . Although no significant side effects have been reported from about 5,500 administrations of Ca-or Zn-DTPA (Voelz 2001; Waller et al. 2002) , repeated doses of Ca-DTPA within a short period of time may cause gastrointestinal distress, chills, fever, muscle cramps, headache, chest pain, etc. (USDOE 2013; Rump et al. 2016 ). Moreover, care should be applied when administering DTPA to pregnant women or people with kidney diseases (NCRP 1980 (NCRP , 2008 USDOE 2013) .
While administration of DTPA is effective in removing the activity that has become systemic, some experimental studies have indicated that plutonium residing in the primary sites of deposition such as wounds can also be decorporated to a certain extent (e.g., Gray et al. 1994 ). Compared to DTPA administration, surgical removal of the contaminant has the potential to avert higher doses, both local and systemic. There are, however, certain risks associated with surgical intervention. One of the wound cases followed for several decades after injury reported a pain-causing nodule several months after treatment (Falk et al. 2006) . Another case discussed by Carbaugh et al. (2010) reported a slight tissue defect and sensitivity to cold 24-y post injury. Although many of the risks of surgical excision may not have been reported in the literature either because of the lack of long-term follow-up of the subjects or because the literature is focused on dosimetric management of the cases, the possibility of side-effects-for example, increased risk to tendons and nerves, damage to healthy tissue, an infection, or even a loss of function-due to surgical excision cannot be disregarded.
As with any medical treatment, the decision to excise a wound or undergo a chelation treatment is a cost-benefit analysis, the benefit being the doses "saved" due to medical treatment and the cost being the potential side-effects of medical treatment. Although this decision is ultimately a joint decision between the patient and the physician, it is important that this decision is informed by dosimetric considerations. To this end, the responsibility of an internal dosimetrist is to provide guidance to both the patient and the treating physician about the potential dose reductions that may be achieved by administration of medical treatment. The objective of this paper was to review several actinide-contaminated wounds in the literature to gain information on the effectiveness of medical procedures after wound contamination. In addition, the authors also evaluate several guidelines for consideration of medical treatment using the recently developed wound model described in Report No. 156 of National Council on Radiation Protection and Measurements (NCRP 2006) .
INFERENCES FROM THE NCRP 156 WOUND MODEL
The NCRP Report No. 156 proposes a multicompartmental biokinetic wound model to describe the translocation of radioactive materials within and away from the wound site. The generic wound model consists of five compartments: Soluble; Colloid and Intermediate States (CIS); Particles, Aggregates and Bound States (PABS); Trapped Particles and Aggregates (TPA); and Fragments that lead to systemic uptake into the blood or clearance into the lymph nodes. These compartments in the model were conceived based on the understanding of the physical and chemical properties of different kinds of soluble and insoluble radioactive materials. The report divides the category "soluble" into weak, moderate, strong, and avid categories depending on the retention half-times determined from experimental data. Similarly, particulate radionuclides are grouped into three categories of colloid, particle, and fragment based on their physical properties and retention patterns. Firstorder kinetics are used to describe the transfer of material from one compartment to another, and the transfer rates between the compartments for each of the seven default categories are given in the NCRP 156 report (NCRP 2006) .
Wound retention
The NCRP report provides multi-exponential equations that represent the average retention behavior of different categories of radioactive materials in the wound. The total retention in the wound can also be calculated as the sum of the activities retained in each of the five wound compartments. The fractions of intake retained in wounds at various times after the wound deposition as predicted by the NCRP 156 report for the default categories were calculated using the algorithm provided by Birchall and James (1989) and are given in Fig. 1a . The activity calculations in this paper were verified using Activity and Internal Dose Estimates (AIDE) (Bertelli et al. 2008) . As seen in the figure, the "soluble" radioactive materials are cleared from the wound more rapidly than sparingly soluble or insoluble materials. For example, only 34% of the total deposition of weakly-retained plutonium in the wound remains at the wound site at the end of an hour after the wound intake, which decreases to about 7% at the end of 1 d. On the other hand, particles are cleared at a much slower rate with 99.62% of the initial deposition remaining at the wound site at the end of 1 d, which decreases to about 6.5% in 25 y. Fragments are even more tenaciously-retained with close to 97% of the total activity still retained at the wound-site after 25 y.
Measurements of activity in the wound site can be used to obtain an estimate of the actual intake. This is particularly true for particles and fragments, which are retained more strongly in the wound. However, for contaminants of soluble and colloidal chemistries, it is important to consider the fraction of the intake that is already absorbed into the blood. For example, if a person has a wound contaminated with weakly-retained plutonium, a wound count performed after an hour of intake will underestimate the intake by approximately 66%. For soluble and sparingly soluble contaminants, it is therefore important to take into account two things: 1) the time between the incident and the wound measurement, and 2) the retention class to which the contaminant can be assigned. Some information on the latter can be obtained from process knowledge; however, the exact retention category may not be known accurately until the internal dosimetrist can interview the person involved and analyze a series of urinary excretion data and/or wound retention data. For diagnostic purposes, "strongly retained" can be used as a default retention category for plutonium when specific chemistry is unknown.
Urinary excretion
The NCRP 156 wound model can be coupled with an element-specific systemic model via blood, which is a clearance compartment in the wound model and a transfer compartment in the systemic model. This combination of the compartmental models can be solved to obtain information on the activities in each compartment at any time. The 24-h urinary excretion on day t can be obtained by subtracting the cumulative activity in the "urinary compartment" at time t − 1 from that at time t and making corrections for the radioactive decay. The urinary excretion fractions after an intake of different forms of 239 Pu are given in Fig. 1b . These fractions were obtained by coupling the wound model with the ICRP 67 systemic plutonium model (ICRP 1993) .
It is important to note that because the absorption of sparingly soluble and insoluble plutonium from the wounds into the blood is negligible, the urinary excretion due to a wound contaminated with such forms of plutonium is negligible (Fig. 1b) Pu for the alpha spectroscopy system (RAS) used at the Los Alamos National Laboratory (LANL) is 0.24 mBq 24-h À1 urine (LANL 2016) , which translates to a minimum detectable intake of about 291 Bq and 0.85 MBq for particle and fragmental plutonium respectively (using urinary excretion at day 1 post intake). While thermal ionization mass spectroscopy (TIMS) provides higher sensitivity measurements for 239 Pu (LANL 2016), significantly large wound intakes are still not detected by urinalysis if the contaminant is particulate or fragmental plutonium.
Impact of time
Because of the negligible excretion of plutonium from wounds contaminated with insoluble plutonium, wound counts need to be relied upon when making medical decisions after incorporation of radionuclides into wounds. Moreover, collecting and analyzing urine for plutonium content is a time-consuming process relative to the urgency of medical decision making. The time factor is more important for soluble contaminants than insoluble contaminantsapproximately 93%, 68% and 38% of the contaminants of "weakly-retained," "moderately-retained," and "stronglyretained" nature, respectively, are already absorbed into the blood by the end of day 1 after the intake (Fig. 1a) . Therefore, the longer the wait between intake and excision, the smaller are the doses averted.
Similarly, chelation is the most effective immediately after intake and when the majority of the material is still in the extracellular fluid (Stather et al. 1983) , and the effectiveness diminishes with increasing time (NCRP 2008; Rump et al. 2016) . For soluble forms of plutonium, activity in the blood reaches a maximum within a day of intake via wound (Fig. 1b) . Because of this and the fact that chelation treatments are relatively safe, decorporation treatment under the urgent/immediate approach is sometimes recommended in case of suspicion of incorporation of radionuclides † (LLNL 2015; Rump et al. 2016) . This is because a delay can cause a significant loss in efficacy of treatment and cannot be compensated later (Voelz 2001; Rump et al. 2016) . It may, however, be worthwhile to wait for wound assessment (activity, depth, process knowledge, etc.) before starting a more intensive treatment (i.e., surgery). Regardless, it is important that an internal dosimetrist explain to the patient and the treating physician the benefits of prompt medical treatment after an intake via wound.
Dosimetry of contaminated wounds
Dose coefficients for common modes of intake, such as inhalation and ingestion, have been available and in use for decades (e.g., ICRP 1994 (e.g., ICRP , 2012 . However, because of the lack of a standard wound model until the publication of NCRP Report No. 156, dose coefficients for intakes via wound were unavailable. After the publication of the NCRP 156 wound model, systemic dose coefficients can be calculated by coupling the wound models with an elementspecific systemic model. The NCRP 156 report provides systemic dose coefficients for wound intake of uranium of different forms but does not do so for other radionuclides. Instead, the report provides only the upper limits of the dose coefficients for several radionuclides. It is important to note that these upper limits are based on an assumption that all the activity deposited in the wound site become systemic. While these dose coefficients may be very close to the actual dose coefficients for intakes of soluble radionuclides, they may significantly overestimate the dose coefficients due to wound intake of radionuclides in particle or fragment forms.
Recognizing the lack of dose coefficients for wound intakes, Toohey et al. (2011a and b) computed the effective dose coefficients [e(50)] and organ dose coefficients [h T (50)] for intakes via contaminated wounds for several radionuclides commonly encountered in nuclear facilities, medicine, and research. The effective dose coefficients for plutonium isotopes and the equivalent dose coefficients for bone surface (the organ receiving the highest dose) derived from coupling different NCRP 156 wound models with the ICRP 67 systemic model are given in Table 1 .
The dose coefficients can be used to calculate Derived Regulatory Guidance (DRGs); i.e., the values of wound intake (Bq) that would result in an effective dose or organequivalent dose equal to the regulatory limit (Toohey et al. 2011a ). The DRG is given by,
For all categories of plutonium, the DRG is limited by the organ-equivalent dose to the bone surface. These numbers therefore represent the amount of plutonium intake that would result in 0.5 Sv equivalent dose to the bone surface if no medical countermeasures, such as excision or chelation, are undertaken. Although similar in concept to annual limit of intake for other modes of intake, Toohey et al. (2011a) warn that these values should not be interpreted as permissible because intake via wound is not an acceptable pathway for routine operations. Nevertheless, the DRGs are useful as they can inform medical decision making.
It is important to recognize that the dose coefficients provided in Table 1 consider only the radioactive material † Autorité de Sureté Nucléaire. Guide national. Intervention médicale en cas d'évènement nucléaire ou radiologique. Version V 3.6; 20018 (in French). in systemic circulation. Therefore, the dose coefficients are higher (and thus the DRGs are smaller) for soluble radionuclides that are rapidly absorbed into the blood than for fragments, for which only a tiny fraction is absorbed into the blood. The calculation of doses to the wound site is complicated by the lack of proper definition of mass of the wound site (NCRP 2006; Toohey et al. 2011a) . The contribution of the residual activity in the wound site to e(50) and h T (50) is not significant for plutonium but should be considered for high-energy gamma emitters that are retained at the wound site for a long time.
"SAVED DOSES" IN MEDICAL DECISION MAKING
One of the important elements of a medical response plan is the decision levels for determining when an accident requires a medical response (USDOE 2013). Also, as discussed earlier, medical decisions after incorporation of radionuclides into the wound need to be based on limited information on wound measurements. Thus, a question that needs to be answered is what amount of activity in a wound should indicate the need for medical intervention. The NCRP Report No. 156 recommends that the decision for medical treatment be based on computation of "saved doses." The concept of saved doses, as introduced by Toohey et al. (2002 Toohey et al. ( , 2003 , refers to the reduction in the dose that is achieved by medical countermeasures. The report proposes that chelation therapy may be indicated if saved doses are on the order of 1 to 10 times the annual limit, and a drastic intervention such as surgical excision may be appropriate if saved doses exceeding 10 times the annual limit can be achieved. The report (NCRP 2006) emphasizes that while "every case is different" when it comes to medical management of radionuclide-contaminant wounds, an internal dosimetrist can advise the treating physician on "saved doses" based on general understanding of the behavior of contaminants in wounds. In order to estimate the saved doses, it is necessary to have an a priori estimate of the efficacies of medical treatments. The following sections review the health physics literature to obtain information on the efficacies of surgical excisions and chelation treatments following incorporation of plutonium into the wounds and use this information to estimate the wound intakes that would indicate medical intervention.
Administration of DTPA
One of the metrics frequently used to evaluate the efficacy of a DTPA treatment is the enhancement ratio, ER, which compares the urinary excretion after a DTPA treatment to that expected without the treatment.
The urinary excretion after a chelation treatment, e exp , is given by:
where I is the intake and i u is the urinary excretion fraction expected without chelation treatment (obtained from standard biokinetic models). Each chelation treatment decreases the effective intake by increasing the urinary excretion. The decrease in effective intake due to the chelation treatment on the day of intake is then,
which can be used to estimate the doses saved due to chelation, SD C :
where DC is the applicable dose coefficient. One may recall that the NCRP 156 (NCRP 2006) recommends that chelation therapy may be indicated if saved doses on the order of 1 to 10 times the annual limit can be achieved. For plutonium, the annual limits are based on doses to the bone surface. Equation (4) can then be used to estimate the minimum value of wound intake, I DG,C, for which NCRP 156 indicates chelation treatment may be appropriate: In all cases discussed here, the DRG is the amount of wound intake (Bq) that would result in an equivalent dose of 0.5 Sv to the bone surface.
A review of literature on medical management of plutonium intakes shows that administration of DTPA enhances the urinary excretion of plutonium by a factor of 1 to 130 (Norwood 1962; Anderson et al. 1970; Jech et al. 1972; Jolly et al. 1972; Parker 1973; Schofield and Lynn 1973; Piechowski et al. 1989; LaBone 1994a and b; Bailey et al. 2003; James et al. 2007; Bertelli et al. 2010; Davesne et al. 2016; Poudel et al. 2017a ). The urinary enhancement depends on the chemical and physical characteristics of the plutonium compound as well as the time post intake at which chelation was administered (NCRP 2006; Voelz 2001) . For preliminary dose assessment and clinical decision-making purposes, several publications [e.g., SFMT 2011 (Davesne et al. 2016; LaBone 1994a) ] recommend an enhancement ratio of 50. The authors used this ratio to estimate the minimum wound intake for which the NCRP 156 maintains a DTPA administration is indicated (Table 2) .
Surgical excision
To estimate the efficacy of surgical excision in removal of contaminant in the wounds, the authors reviewed several wound cases reported in the literature. The inclusion of the cases in this review was, however, limited by whether the efficacy of surgical treatments could be estimated (i.e., whether information on the deposition in wounds and the estimated activity remaining at the wound site after surgery was reported). The 17 cases reviewed included this information, along with the information on the type of wound, the physicochemistry of the contaminant, and wound measurements (Table 3) .
From the review of several plutonium-contaminated wound cases, it is evident that surgical removal of contaminants or excision of contaminated tissues is highly effective in removing a major fraction of the activity deposited in the wound site. In 16 of the 17 cases reviewed, wound excision was able to remove close to or more than 70% of the contaminant (Table 2 ). This is consistent with Ilyin (2001) , who found that 70-90% of wound radioactivity can be removed by surgical dissection.
If I is the wound intake, Eff is the estimated efficacy of surgical treatment, and DC is the applicable dose The efficacy of surgical excision depends on several factors such as the nature and the depth of the wound, the extent of dispersion, anatomical location of wound and the physicochemistry of the contaminant. The decision guides in this table are based on the surgical efficacies of 70% and 90% based on the literature review. Pu was reduced to 25.5 Bq due mostly to surgical procedures in day 1. Schadilov et al. (2010) A cut in the tight index finger at the third phalanx Pu and Am isotopes Tissues surrounding the wound site were excised about 4.5 h after the injury that reduced the wound counts to near background.
>99%

Avtandilashvili et al. (2017) A wound to the left middle finger Pu nitrate~4.5 kBq of Pu was surgically removed 2.5 h after the incident leaving the residual deposition in the wound at~400 Bq.~9 2% coefficient, then doses saved due to excision, SD S , can be estimated as:
The NCRP Report No. 156 (NCRP 2006) recommends that saved doses exceeding 10 times the annual limit may be appropriate for surgical excision. Equation (7) can then be used to estimate the minimum value of wound intake, I DG,S that would indicate surgical excision as recommended by NCRP 156; i.e.,
The I DG,S for different categories of plutonium have been given in Table 2 . While these numbers have been estimated assuming 70% and 90% efficacies of surgical excision, it is important to note that each wound case is different.
OTHER GUIDELINES
The Guidebook for the Treatment of Accidental Internal Radionuclide Contamination of Workers (CEC/DOE Guidebook) recommends that medical treatment be considered when the estimated committed effective dose [e(50)] for an intake is between 20 mSv and 200 mSv (Gerber and Thomas 1992) . The guidebook strongly recommends treatment for intakes with estimated e(50) greater than 200 mSv. These guidelines are also reflected in the U.S. Department of Energy (DOE) Standard Good Practices for Occupational Protection in Plutonium Facilities (USDOE 2013). While 20 mSv is a relatively low threshold for consideration of medical treatment, it may be justifiable based on the fact that there are several uncertainties associated with the initial dose estimates made within hours of intake. The corresponding wound intakes are given in Table 4 .
The NCRP Report No. 161, Management of Persons Contaminated with Radionuclides: Handbook, (NCRP 2008) introduces Clinical Decision Guides (CDGs) aimed to guide physicians in considering the need for a medical treatment for internally deposited radionuclides. The report defines CDG as the intake that warrants medical intervention to reduce the internal dose. To limit both the stochastic and the deterministic effects, the CDG is the most limiting of the intake amount (besides that of radioiodines) that would result in 250 mSv effective dose, 250 mGy 30-d RBE-weighted dose to red marrow or 1 Gy 30-d absorbed dose to lung (NCRP 2008); i.e., Table 4 . Wound intake levels corresponding to decision guides. where d RM and d Lung are the RBE-weighted absorbed dose coefficients for red marrow and lung respectively. For plutonium wound intakes, the CDG is limited by the effective dose. Table 4 contains the CDGs for wound intakes of various plutonium chemistries based on NCRP 156.
LIMITATIONS
As discussed earlier, medical decisions often need to be made on the basis of limited information on estimated activity in the wound. For radionuclides that emit only particulate and/or low energy photon radiations, one of the common problems with wound counting is quantifying the effects of self-absorption of wound deposited material (Hickman 2006; NCRP 2006) . In addition, factors such as the geometry of the embedded material, the source-to-detector distance, and the depth of the contaminant in the skin are also important in determining the efficiency of wound counting (Hickman et al. 1994 ). Hammond and Putzier (1964) reported that the efficiency changes by up to a factor of six when the depth of the tissue equivalent material changes from zero to one-fourth of an inch. While several methods are available for estimation of the depth of contaminant (e.g., Palmer et al. 1968; Johnson and Lawrence 1974) , even the slightest error in estimation of depth will cause a huge difference in the estimation of the efficiency of L x rays, which may result in significant under-or overestimation of the activity in the wound. It is, however, important to note that prompt measurements, although less accurate, are useful in decision making after internal contamination (NCRP 2017) .
The dosimetric considerations in clinical decision making after a plutonium-contaminated wound are complicated by the fact that a person in any nuclear facility is involved with a wide variety of forms of actinides. For example, an analysis of thousands of workers at the Mayak Association revealed that a majority of the workers were involved with both "poorly transportable" and "relatively transportable" classes of actinide compounds (Ilyin 2001) . Therefore, a wound intake may not be exclusively explained by the biokinetic model for a single specific category within the NCRP 156 framework. Often, a combination of wound models is required to describe the bioassay and the wound/ organ-retention data after a plutonium wound intake } (e.g., James et al. 2007; Poudel et al. 2017b) . While sum-offractions may be used to guide medical decision in cases of contamination by different forms of plutonium, the exact fractions of the contaminants are not known until a series of wound-retention or urinary analysis data is analyzed by an internal dosimetrist. One approach may be to put decision guidelines in place for standard mixtures to which any employee at a certain facility is most likely to be exposed. Another approach is to have a simple conservative guideline to aid in medical decision making. For example, the LANL procedure (LANL 2014) recommends that surgical excision be considered if the total plutonium or transuranic activity in the wound is greater than 37 Bq. Assuming that all of the activity ( 239 Pu) becomes systemic (most conservative), this corresponds to a committed effective dose of 18 mSv and an equivalent dose of 610 mSv to bone surface. While this may be too conservative for insoluble plutonium, it ensures that local doses to the wound site are also minimized.
The decision guidelines based on effective doses and organ doses calculated above were obtained from coupling the NCRP 156 wound model with the ICRP 67 systemic plutonium model. Because of the paucity of biokinetic data from unperturbed wound exposures, the NCRP 156 wound model was parameterized using the wound retention data from experimental animal studies (Guilmette and Durbin 2003; NCRP 2006) . The authors of the report acknowledged this limitation and encouraged application and validation using human bioassay data (Guilmette et al. 2007) . A review ** of the applications of the wound models have indicated that the wound model is capable of describing the bioassay data in many cases, but adjustments to some (e.g. Schadilov et al. 2010; Carbaugh et al. 2010 ) or all (e.g., Miller et al. 2008 Miller 2010 ) model parameters may be necessary in other cases. So, when using the NCRP 156 wound model to calculate projected doses or averted doses, it is important to understand this limitation of the wound model.
It is also important to reiterate that the decision guidelines discussed above are based on either the organequivalent dose (to bone surfaces) or effective doses, and thus they take into account only the activity that is absorbed from the wounds into the blood. As such, the decision guidelines for wound intakes of sparingly soluble and insoluble chemistries are fairly large. For example, the decision guide for chelation for wound intakes of fragmental plutonium based on the concept of saved doses is 7.89 Â 10 10 Bq. This is because there is practically no absorption of fragmental plutonium from the wound into the blood, so it takes a huge amount of plutonium to result in a benefit of doses saved equal to the annual limit. Similarly, removal by surgical excision is indicated only for intakes on the order of tens of thousands of becquerels. The decision guidelines based on the systemic doses alone-particularly for particles and fragments-may not be appropriate because they do not take into account the local doses to the wound site.
The recommendation of CEC/DOE on the use of effective dose in medical decision making is based on the risks of late health effects, primarily the risk of carcinogenesis. The effective dose, however, is not a good measure to assess the probability of cancer induction (Fisher and Fahey 2017) . Moreover, the Health Physics Society (HPS) advises against estimating health risks from exposures below levels of about 100 mSv above the background (HPS 2016). Also, because the dose-response relationship at low doses is still not well understood, the decision of medical treatment is based on risks that are not well understood (Voelz 2001) .
While the systemic doses are more important from a regulatory perspective, the effects due to local irradiation of the tissue cannot be ignored. The NCRP (NCRP 2006) recommends using dosimetry models for shallow (NCRP 1989 (NCRP , 1999 or penetrating (e.g., Stabin 1996) wounds to estimate local doses to the wound site as applicable. An example of severe local effects due to a plutonium contaminated wound was reported by Lushbaugh and Langham (1962) in which an autoradiographic examination revealed radiodermatitis after about 4 y of implantation in the skin. NCRP Report No. 156 (NCRP 2006) recommends that the local doses from contaminated wounds be limited by the principle in the same way as that for "hot particles" as described in NCRP Report No. 130 (NCRP 1999); i.e., "preclusion of the development of ulcers that would compromise the integrity of the skin as a barrier to infection." In addition, metallic foreign implants-radioactive or nonradioactive-may have the potential to induce sarcomas (Jennings et al. 1988; Guilmette et al. 1989; Hahn et al. 2002) . Although such incidences are low (NCRP 2006) , clinical decision making should also consider the possible patho-physiological response of the tissue in addition to the local and systemic doses.
Medical care always takes precedence over decontamination and decorporation efforts. The first priority after a wound incident is to achieve homeostasis and take actions to preserve physiologic and anatomic function (NCRP 2006 (NCRP , 2008 . The physician should also consider the general health and age of the individual before deciding the treatment (Voelz 2001; Cassatt et al. 2008; DominquezGadea and Cerezo 2011) . The benefit vs. risk of treatments is higher for younger and healthier individuals than for older and relatively unhealthy individuals, so younger and healthier individuals can be treated more aggressively as needed (Voelz 2001) .
Finally, any radiological incident is bound to cause psychological distress in the persons involved and their families. The treating physician, therefore, should consider the psychology of the patients and their families. For some, it is important to feel confident that everything possible is being done to reduce the dose. For others, treatment that is not expected to yield any health benefit may seem a waste of time. In addition, the anxiety and stress associated with undergoing a chelation treatment or surgical excision, regardless of the expected health benefit, may itself be a significant factor in making a clinical decision.
CONCLUSION
Some important conclusions regarding medical intervention after plutonium wound intakes can be drawn from the NCRP 156 wound model: 1) time is an important factor in medical decision making, so such a decision needs to be based on limited information available; and 2) chelation treatment is more effective for soluble plutonium, whereas surgical excision is more appropriate for particles and fragments. The review of literature demonstrated that surgical excision is highly effective in removing the activity deposited in the wounds. Similarly, chelation can enhance the urinary excretion by a factor of 1 to 130, taken on average to be 50.
While the use of the effective doses in clinical decision making can be debated, the current body of guidelines recommends using effective dose for consideration of medical intervention. The authors presented wound intakes for various forms of plutonium corresponding to the dose limits recommended by CEC/DOE. Based on the recommendations of NCRP 156, they also calculated the wound intakes that would indicate that chelation and surgical excision would avert the doses in the order of 1 or 10 times the annual limit, respectively. It is important to note that these guidelines do not consider the effect of local irradiation and the pathophysiological response of the tissue, which should be considered, especially for particles and fragments. The decision making after plutonium-contaminated wounds is further complicated by the fact that a person involved may be working with forms of plutonium that cannot be exclusively assigned to an NCRP 156 category, and the exact form is not known until a series of urine/wound-retention data is analyzed.
Finally, it is important to understand that each wound case is different with respect to the nature of the contaminant (i.e., solubility, physico-chemistry, particle size, and mass), the nature and the depth of the wound (i.e., abrasion, laceration, burn, or a puncture wound), the anatomical location, and the extent of dispersion. While an internal dosimetrist can provide the physician with knowledge on the benefit of a medical treatment (i.e., projected averted doses based on knowledge of work processes, material forms, and past experience) using the general calculations in this report, the treating physician must make the judgment by considering the risks vs. benefit of each treatment on a case-by-case basis. Such analysis must factor in the emotional and psychological distress suffered or that will be suffered by the affected person and his/her family.
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